Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients

Global data on the treatment rate with direct‐acting antivirals (DAAs) for chronic hepatitis C (CHC) are sparse. We aimed to evaluate the CHC treatment rate and barriers to treatment in the DAA era.

• Publication year

  2023

• Venue

  Liver international (Print)

• Publication date

  2023-02-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/liv.15550PMID 36825358
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma

  2022cited by this paper
• Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.

  2022cited by this paper
• Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

  2022cited by this paper
• Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis

  2022cited by this paper
• Progress towards elimination of viral hepatitis by 2030 in the WHO Eastern Mediterranean Region, 2019.

  2022cited by this paper
• Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study

  2021cited by this paper
• Shelter‐Based Integrated Model Is Effective in Scaling Up Hepatitis C Testing and Treatment in Persons Experiencing Homelessness

  2021cited by this paper
• Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

  2021cited by this paper
• Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West

  2020cited by this paper
• Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C

  2020cited by this paper
• HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort

  2020cited by this paper
• Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis.

  2020cited by this paper
• Liver Care and Surveillance: The Global Impact of the COVID‐19 Pandemic

  2020cited by this paper
• Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013‐2016

  2020cited by this paper
• HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.

  2019cited by this paper
• Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.

  2019cited by this paper
• Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

  2019cited by this paper
• Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis

  2019cited by this paper
• Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

  2019cited by this paper
• Progress and Challenges in a Pioneering Hepatitis C Elimination Program in the Country of Georgia, 2015-2018.

  2019cited by this paper
• Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis

  2018cited by this paper
• EASL Recommendations on Treatment of Hepatitis C 2018.

  2018cited by this paper
• EASL Recommendations on Treatment of Hepatitis C 2016.

  2017cited by this paper
• Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study

  2017cited by this paper
• Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

  2017cited by this paper
• Managing drug–drug interactions with new direct‐acting antiviral agents in chronic hepatitis C

  2017cited by this paper
• Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities

  2017cited by this paper
• All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database

  2017cited by this paper
• Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals

  2016cited by this paper
• Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.

  2016cited by this paper
• Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

  2016cited by this paper
• Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

  2016cited by this paper
• APASL consensus statements and recommendation on treatment of hepatitis C

  2016cited by this paper
• Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

  2016cited by this paper
• Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade

  2015cited by this paper
• Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

  2015cited by this paper
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  2009cited by this paper
• The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002

  2006cited by this paper
• Prevalence of hepatitis C virus infection in the United States.

  1999cited by this paper
• [The prevalence of hepatitis C virus infection].

  1998cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper

• Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort

  2026cites this paper
• Peer-delivered mail-order self-collection and linkage to treatment for hepatitis C virus infection among users of a harm reduction service in Denmark.

  2025cites this paper
• Steatotic liver disease is the dominant indication for liver transplantation in both europe and the United States: Trends and outcomes in the past two decades.

  2025cites this paper
• Expanding treatment indications in chronic hepatitis B: Should we treat all patients?

  2025cites this paper
• Prevalence of Hepatitis C Virus and HIV among Libyans and Expatriates (Foreigners) in the City of Zawia, Libya

  2025cites this paper
• Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs

  2024cites this paper
• Hepatitis C Infection Confirmation and Fewer Visits Contribute to Improving Treatment Rates in a Predominantly African American Health Center

  2024cites this paper
• Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?

  2024cites this paper
• Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis

  2024cites this paper
• Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease

  2024cites this paper
• Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply

  2024cites this paper
• Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions

  2024cites this paper
• World Hepatitis Day 2023: Are we close to the target?

  2023cites this paper
• Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease

  2023cites this paper
• Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark.

  2023cites this paper